Endocrine Abstracts

Introduction: Patients with adrenal incidentalomas and sub-clinical Cushing’s (SCH) have increased cardiovascular events and mortality. We hypothesised that these patients have a disturbed cortisol rhythm amenable to being restored to normal by using timed short-acting cortisol synthesis blockade, and that this may have a positive effect on IL6 levels.Methods: In a phase 1, prospective study (Eudract No. 2012-002586-35) we recruited eight patients w...

Introduction: Current medical treatment of adrenocortical carcinoma (ACC) is based on mitotane alone or in combination with cytotoxic chemotherapy. However, very little is known about the pharmacokinetic properties of mitotane and dosing schedules are based on clinical experience only. The aim of this study was to investigate the relationship between mitotane dose and plasma concentration comparing two pre-defined treatment regimens. Secondary objectives were to evaluate safet...

Introduction: O,p’DDD is the drug of choice for patients with adrenocortical carcinoma (ACC). Monitoring o,p’DDD serum level has been proposed as predictor of tumour response. Measurement of o,p’DDD metabolites involved in the active pathway may provide an improved prediction of o,p’DDD activity. The objective of our study was to (1)to confirm the currently used threshold o,p’DDD serum level of 14mg/l for achieving a tumour response and (2)compare the ...